ETF fact sheet · XBI · Biotech
State Street SPDR S&P Biotech ETF
The model values 29 of XBI's 152 holdings. At the median their price sits 0.6% below its fair value, and 69% of them are priced below it.
Among the holdings the model backs with medium or high evidence, the cheapest by its reckoning is Protagonist Therapeutics (PTGX), priced 15.5% below fair value, and the priciest is Moderna (MRNA), priced 15.5% above fair value. That is the model's opinion, not advice.
The fund through Faircurve's model, from its run of 24 Oct 2026; closes to 27 Oct 2026.
Last close$154.84+2.90% on the day
This year+26.99%-1.97% against the S&P 500 over a month
Beta1.32moves about 1.3 times as much as the market
Price vs fair value0.6% belowthe median of 29 holdings the model values; 69% priced below
XBI through the model
| Holding | Weight | 1D | Price vs fair value | Evidence |
|---|---|---|---|---|
| MRNA Moderna | 2.6% | +4.59% | 15.5% above | medium |
| NTRA Natera | 1.8% | not covered | ||
| HALO Halozyme Therapeutics | 1.7% | +0.38% | 4.0% above | medium |
| BIIB Biogen | 1.7% | +0.19% | 0.6% below | medium |
| ABBV AbbVie | 1.7% | -0.10% | 2.2% below | high |
| TWST Twist Bioscience | 1.7% | not covered | ||
| IOVA Iovance Biotherapeutics | 1.7% | not covered | ||
| AMGN Amgen | 1.7% | +0.75% | 5.0% below | medium |
| EXEL Exelixis | 1.6% | +0.37% | 0.2% below | medium |
| UTHR United Therapeutics | 1.6% | -0.28% | 2.2% above | medium |
| GILD Gilead Sciences | 1.6% | +0.25% | 3.5% above | medium |
| SYRE Spyre Therapeutics | 1.6% | not covered | ||
| REGN Regeneron Pharmaceuticals | 1.5% | +1.04% | 4.9% below | medium |
| TGTX TG Therapeutics | 1.5% | +3.01% | 0.5% below | low |
| VRTX Vertex Pharmaceuticals | 1.5% | +0.68% | 3.7% above | medium |
| ALKS Alkermes | 1.4% | -0.27% | 10.4% above | medium |
| RVMD Revolution Medicines | 1.4% | not covered | ||
| PTGX Protagonist Therapeutics | 1.4% | +0.57% | 15.5% below | medium |
| KRYS Krystal Biotech | 1.4% | +2.21% | 15.5% below | medium |
| PTCT PTC Therapeutics | 1.4% | +1.67% | 0.8% below | medium |
| INCY Incyte | 1.4% | +2.90% | 15.5% below | medium |
| CRSP Crispr Therapeutics AG | 1.4% | not covered | ||
| NBIX Neurocrine Biosciences | 1.4% | +0.09% | 6.8% below | medium |
| ALNY Alnylam Pharmaceuticals | 1.3% | -0.38% | 12.1% below | medium |
| PCVX Vaxcyte | 1.3% | not covered | ||
| BBIO Bridgebio Pharma | 1.3% | not covered | ||
| BMRN Biomarin Pharmaceutical | 1.3% | -0.72% | 14.5% below | medium |
| ORKA Oruka Therapeutics | 1.3% | not covered | ||
| CYTK Cytokinetics | 1.3% | +1.30% | 19.1% above | low |
| MDGL Madrigal Pharmaceuticals | 1.3% | not covered | ||
| ROIV Roivant Sciences | 1.2% | +1.36% | 6.2% above | medium |
| ERAS Erasca | 1.2% | not covered | ||
| GRAL Grail | 1.2% | not covered | ||
| COGT Cogent Biosciences | 1.2% | not covered | ||
| KYMR Kymera Therapeutics | 1.2% | not covered | ||
| IONS Ionis Pharmaceuticals | 1.2% | not covered | ||
| KOD Kodiak Sciences | 1.2% | not covered | ||
| TVTX Travere Therapeutics | 1.2% | not covered | ||
| PRAX Praxis Precision Medicines I | 1.1% | not covered | ||
| INSM Insmed | 1.1% | +1.75% | 1.0% below | low |
| DNTH Dianthus Therapeutics | 1.1% | not covered | ||
| RYTM Rhythm Pharmaceuticals | 1.1% | not covered | ||
| ARWR Arrowhead Pharmaceuticals | 1.1% | +0.08% | withheld | |
| MIRM Mirum Pharmaceuticals | 1.0% | not covered | ||
| VCYT Veracyte | 1.0% | +4.32% | 2.4% below | medium |
| TNGX Tango Therapeutics | 1.0% | not covered | ||
| IBRX Immunitybio | 1.0% | not covered | ||
| ARQT Arcutis Biotherapeutics | 1.0% | not covered | ||
| CGON CG Oncology | 1.0% | not covered | ||
| VKTX Viking Therapeutics | 0.9% | not covered | ||
| CDNA Caredx | 0.9% | not covered | ||
| RLAY Relay Therapeutics | 0.9% | not covered | ||
| BEAM Beam Therapeutics | 0.9% | not covered | ||
| RARE Ultragenyx Pharmaceutical IN | 0.8% | not covered | ||
| SRRK Scholar Rock | 0.8% | not covered | ||
| CELC Celcuity | 0.7% | not covered | ||
| DYN Dyne Therapeutics | 0.7% | not covered | ||
| SLS Sellas Life Sciences Group I | 0.7% | not covered | ||
| AGIO Agios Pharmaceuticals | 0.6% | not covered | ||
| RXRX Recursion Pharmaceuticals A | 0.6% | not covered | ||
| IMVT Immunovant | 0.6% | not covered | ||
| SMMT Summit Therapeutics | 0.6% | not covered | ||
| DNLI Denali Therapeutics | 0.6% | not covered | ||
| NRIX Nurix Therapeutics | 0.6% | not covered | ||
| IRON Disc Medicine | 0.6% | not covered | ||
| SRPT Sarepta Therapeutics | 0.6% | +5.06% | 20.1% below | low |
| IDYA Ideaya Biosciences | 0.6% | not covered | ||
| VRDN Viridian Therapeutics | 0.6% | not covered | ||
| VERA Vera Therapeutics | 0.6% | not covered | ||
| PURR Hyperliquid Strategies | 0.5% | not covered | ||
| BCRX Biocryst Pharmaceuticals | 0.5% | not covered | ||
| NVAX Novavax | 0.5% | not covered | ||
| ADMA Adma Biologics | 0.5% | +0.90% | 0.5% below | low |
| NTLA Intellia Therapeutics | 0.5% | not covered | ||
| ACAD Acadia Pharmaceuticals | 0.5% | +2.18% | 0.3% below | low |
| RCUS Arcus Biosciences | 0.5% | +2.14% | 11.7% above | medium |
| CLDX Celldex Therapeutics | 0.5% | not covered | ||
| QURE Uniqure NV | 0.5% | not covered | ||
| PVLA Palvella Therapeutics | 0.4% | not covered | ||
| ABSI Absci | 0.4% | not covered | ||
| VCEL Vericel | 0.4% | +0.53% | 0.4% below | low |
| BHVN Biohaven | 0.4% | not covered | ||
| PGEN Precigen | 0.4% | not covered | ||
| NKTR Nektar Therapeutics | 0.4% | not covered | ||
| TRAX First Tracks Biotherapeu W/I | 0.4% | not covered | ||
| IMNM Immunome | 0.3% | not covered | ||
| STOK Stoke Therapeutics | 0.3% | not covered | ||
| SNDX Syndax Pharmaceuticals | 0.3% | not covered | ||
| ORIC Oric Pharmaceuticals | 0.3% | not covered | ||
| XNCR Xencor | 0.3% | +2.78% | withheld | |
| MLYS Mineralys Therapeutics | 0.3% | not covered | ||
| INBX Inhibrx Biosciences | 0.3% | not covered | ||
| ZBIO Zenas Biopharma | 0.3% | not covered | ||
| ANAB Anaptysbio | 0.3% | not covered | ||
| REPL Replimune Group | 0.3% | not covered | ||
| VIR VIR Biotechnology | 0.3% | +4.80% | 9.3% below | medium |
| JBIO Jade Biosciences | 0.3% | not covered | ||
| KURA Kura Oncology | 0.3% | not covered | ||
| GLUE Monte Rosa Therapeutics | 0.2% | not covered | ||
| TYRA Tyra Biosciences | 0.2% | not covered | ||
| ARDX Ardelyx | 0.2% | not covered | ||
| RIGL Rigel Pharmaceuticals | 0.2% | not covered | ||
| ANNX Annexon | 0.2% | not covered | ||
| GERN Geron | 0.2% | not covered | ||
| MNKD Mannkind | 0.2% | not covered | ||
| TSHA Taysha Gene Therapies | 0.2% | not covered | ||
| VSTM Verastem | 0.2% | not covered | ||
| VOR VOR Biopharma | 0.2% | not covered | ||
| BCAX Bicara Therapeutics | 0.2% | not covered | ||
| JANX Janux Therapeutics | 0.2% | not covered | ||
| CADL Candel Therapeutics | 0.2% | not covered | ||
| CRVS Corvus Pharmaceuticals | 0.2% | not covered | ||
| IMMX Immix Biopharma | 0.2% | not covered | ||
| CGEM Cullinan Therapeutics | 0.2% | not covered | ||
| AVTX Avalo Therapeutics | 0.2% | not covered | ||
| COAG Hemab Therapeutics | 0.2% | not covered | ||
| AVBP Arrivent Biopharma | 0.2% | not covered | ||
| KLRA Kailera Therapeutics | 0.2% | not covered | ||
| MYGN Myriad Genetics | 0.2% | not covered | ||
| OLMA Olema Pharmaceuticals | 0.2% | not covered | ||
| FDMT 4D Molecular Therapeutics IN | 0.2% | not covered | ||
| SVRA Savara | 0.2% | not covered | ||
| DMRA Damora Therapeutics | 0.1% | not covered | ||
| RGNX Regenxbio | 0.1% | not covered | ||
| PRME Prime Medicine | 0.1% | not covered | ||
| ACHV Achieve Life Sciences | 0.1% | not covered | ||
| SANA Sana Biotechnology | 0.1% | not covered | ||
| CTMX Cytomx Therapeutics | 0.1% | not covered | ||
| ALLO Allogene Therapeutics | 0.1% | not covered | ||
| SGMT Sagimet Biosciences INC A | 0.1% | not covered | ||
| ABUS Arbutus Biopharma | 0.1% | not covered | ||
| IRWD Ironwood Pharmaceuticals | 0.1% | not covered | ||
| CAPR Capricor Therapeutics | 0.1% | not covered | ||
| CLYM Climb BIO | 0.1% | not covered | ||
| SLDB Solid Biosciences | 0.1% | not covered | ||
| EDIT Editas Medicine | 0.1% | not covered | ||
| STTK Shattuck Labs | 0.1% | not covered | ||
| DSGN Design Therapeutics | 0.1% | not covered | ||
| ALT Altimmune | 0.1% | not covered | ||
| MNPR Monopar Therapeutics | 0.1% | not covered | ||
| EBS Emergent Biosolutions | 0.1% | not covered | ||
| SPRY ARS Pharmaceuticals | 0.1% | not covered | ||
| OCGN Ocugen | 0.1% | not covered | ||
| AKTS Aktis Oncology | 0.1% | not covered | ||
| CABA Cabaletta BIO | 0.1% | not covered | ||
| PRTA Prothena | 0.1% | not covered | ||
| MDXG Mimedx Group | 0.1% | not covered | ||
| VNDA Vanda Pharmaceuticals | 0.1% | not covered | ||
| NGNE Neurogene | 0.1% | not covered | ||
| OVID Ovid Therapeutics | 0.1% | not covered | ||
| ASMB Assembly Biosciences | 0.1% | not covered | ||
| AURA Aura Biosciences | 0.1% | not covered |
The 15 largest holdings by weight; the button shows all 152. Holdings as of 21 Oct 2026; closes to 27 Oct 2026; the model's run of 24 Oct 2026. Green is a price below the model's fair value, red above it. Not covered: the model does not value it. Withheld: its own checks flag the valuation.
How XBI has moved
| Period | Price return |
|---|---|
| One day | +2.90% |
| One week | +1.04% |
| One month | -1.26% |
| This year | +26.99% |
| One month against the S&P 500 | -1.97% |
One week is seven calendar days, one month 28. Beta 1.32 over the past 60 sessions: the fund moves about 1.3 times as much as the market.
What XBI is
State Street SPDR S&P Biotech ETF holds biotechnology companies, equal weight.
| Expense ratio | 0.35% a year |
|---|---|
| Assets | $10.2 billion |
| Dividend yield | 0.35% ($0.54 paid over twelve months) |
| Holdings | 165 |
| Since | 2006 |
| Issuer | SPDR |
Sectors, share of the fund
| Healthcare | 99.3% |
|---|---|
| Financial Services | 0.7% |